Co-Authors
This is a "connection" page, showing publications co-authored by ADEL K EL-NAGGAR and GUILLERMINA LOZANO.
Connection Strength
3.087
-
Mutant p53 protects triple-negative breast adenocarcinomas from ferroptosis in vivo. Sci Adv. 2024 Feb 16; 10(7):eadk1835.
Score: 0.247
-
Triple-negative breast tumors are dependent on mutant p53 for growth and survival. Proc Natl Acad Sci U S A. 2023 08 22; 120(34):e2308807120.
Score: 0.238
-
Differential Gain-of-Function Activity of Three p53 Hotspot Mutants In Vivo. Cancer Res. 2022 05 16; 82(10):1926-1936.
Score: 0.219
-
p73 gene alterations and expression in primary oral and laryngeal squamous carcinomas. Carcinogenesis. 2001 May; 22(5):729-35.
Score: 0.204
-
Dicer1 Phosphomimetic Promotes Tumor Progression and Dissemination. Cancer Res. 2019 05 15; 79(10):2662-2668.
Score: 0.176
-
Somatic Trp53 mutations differentially drive breast cancer and evolution of metastases. Nat Commun. 2018 09 27; 9(1):3953.
Score: 0.170
-
Synergistic and additive effect of retinoic acid in circumventing resistance to p53 restoration. Proc Natl Acad Sci U S A. 2018 02 27; 115(9):2198-2203.
Score: 0.163
-
Spatio-Temporal Genomic Heterogeneity, Phylogeny, and Metastatic Evolution in Salivary Adenoid Cystic Carcinoma. J Natl Cancer Inst. 2017 10 01; 109(10).
Score: 0.159
-
Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes. Oncogene. 2018 01 18; 37(3):332-340.
Score: 0.158
-
Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations. Clin Cancer Res. 2016 Feb 01; 22(3):725-33.
Score: 0.140
-
Pla2g16 phospholipase mediates gain-of-function activities of mutant p53. Proc Natl Acad Sci U S A. 2014 Jul 29; 111(30):11145-50.
Score: 0.127
-
Therapeutic efficacy of p53 restoration in Mdm2-overexpressing tumors. Mol Cancer Res. 2014 Jun; 12(6):901-11.
Score: 0.124
-
Multiple stress signals activate mutant p53 in vivo. Cancer Res. 2011 Dec 01; 71(23):7168-75.
Score: 0.105
-
Differential gene expression profiling of aggressive and nonaggressive follicular carcinomas. Hum Pathol. 2011 Sep; 42(9):1213-20.
Score: 0.101
-
Mdm2 and Mdm4 loss regulates distinct p53 activities. Mol Cancer Res. 2008 Jun; 6(6):947-54.
Score: 0.083
-
High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. Hum Pathol. 2007 Oct; 38(10):1553-62.
Score: 0.078
-
Mammary tumor modifiers in BALB/cJ mice heterozygous for p53. Mamm Genome. 2007 May; 18(5):300-9.
Score: 0.078
-
A genetic mouse model for metastatic lung cancer with gender differences in survival. Oncogene. 2007 Oct 18; 26(48):6896-904.
Score: 0.077
-
p21 delays tumor onset by preservation of chromosomal stability. Proc Natl Acad Sci U S A. 2006 Dec 26; 103(52):19842-7.
Score: 0.075
-
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 2004 Dec 17; 119(6):861-72.
Score: 0.065
-
Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet. 2004 Jan; 36(1):63-8.
Score: 0.061
-
An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene. 2001 Jul 05; 20(30):4041-9.
Score: 0.052
-
High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci U S A. 2000 Apr 11; 97(8):4174-9.
Score: 0.047
-
Mapping and mutational analysis of the human TAF2G gene encoding a p53 cofactor. Genomics. 1999 Apr 01; 57(1):182-3.
Score: 0.044
-
Constitutive Dicer1 phosphorylation accelerates metabolism and aging in vivo. Proc Natl Acad Sci U S A. 2019 01 15; 116(3):960-969.
Score: 0.043
-
p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell. 2012 Jun 12; 21(6):793-806.
Score: 0.027
-
Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J Clin Invest. 2011 Mar; 121(3):893-904.
Score: 0.025